Impact of the renin-angiotensin system on cardiac energy metabolism in heart failure

Journal of Molecular and Cellular Cardiology

Volumn 63, Issue , 2013, Pages 98-106

  Mori, Jun ^a   Zhang, Liyan ^a   Oudit, Gavin Y ^a   Lopaschuk, Gary D ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

ACC; ACE; ACE2; AMPK; Ang I; Ang II; Angiotensin II; AT1R; AT2R; ATGL; ATP; Cardiac energy metabolism; CPT 1; ERR ; GLUT; GPCR; HF PEF; HF REF; Insulin resistance; MCAD; MCD; MFN2; Mitochondria; MRNA; NADPH; NOS; PDH; PDK; PKC; PPAR ; RAS; Reactive oxygen species; ROS; Sirt; Sirtuins; TNF ; VSMC

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; BECLIN 1; ESTROGEN RELATED RECEPTOR ALPHA; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; MITOFUSIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE B; PYRUVATE DEHYDROGENASE; SIRTUIN 1; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; TRANSCRIPTION FACTOR E2F1;

AUTOPHAGY; CARBOHYDRATE METABOLISM; DOWN REGULATION; ENERGY METABOLISM; FATTY ACID OXIDATION; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE CELL; HEART PROTECTION; HUMAN; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UPREGULATION;

ACC; ACE; ACE2; ACETYL COA CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ADIPOSE TRIGLYCERIDE LIPASE; AMP-ACTIVATED PROTEIN KINASE; AMPK; ANG I; ANG II; ANG II TYPE 1 RECEPTOR; ANG II TYPE 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN I; ANGIOTENSIN II; AT1R; AT2R; ATGL; ATP; CARDIAC ENERGY METABOLISM; CARNITINE PALMITOYL TRANSFERASE-1; CPT-1; ERRΑ; ESTROGEN RELATED RECEPTOR Α; G-PROTEIN COUPLED RECEPTOR; GLUCOSE TRANSPORTER; GLUT; GPCR; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART FAILURE WITH REDUCED EJECTION FRACTION; HF-PEF; HF-REF; INSULIN RESISTANCE; MALONYL COA DECARBOXYLASE; MCAD; MCD; MEDIUM CHAIN ACYL COA DEHYDROGENASE; MESSENGER RNA; MFN2; MITOCHONDRIA; MITOFUSIN 2; MRNA; NADPH; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; NITRIC OXIDE SYNTHASE; NOS; PDH; PDK; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR Α; PKC; PPARΑ; PROTEIN KINASE C; PYRUVATE DEHYDROGENASE; PYRUVATE DEHYDROGENASE KINASE; RAS; REACTIVE OXYGEN SPECIES; RENIN-ANGIOTENSIN SYSTEM; ROS; SIRT; SIRTUIN; SIRTUINS; TNF-Α; TUMOUR NECROSIS FACTOR-Α; VASCULAR SMOOTH MUSCLE CELL; VSMC;

ANGIOPOIETINS; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; CARBOHYDRATE METABOLISM; ENERGY METABOLISM; FATTY ACIDS; HEART; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MITOCHONDRIA; MYOCARDIUM; OXIDATION-REDUCTION; PEPTIDYL-DIPEPTIDASE A; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84881507866     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2013.07.010     Document Type: Review

References (136)

1. Serneri G.G., Boddi M., Cecioni I., Vanni S., Coppo M., Papa M.L., et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ. Res. 2001, 88:961-968.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. 1991, 325:293-302.
3. Granger C.B., McMurray J.J., Yusuf S., Held P., Michelson E.L., Olofsson B., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003, 362:772-776.
4. Chiu A.T., Roscoe W.A., McCall D.E., Timmermans P.B. Angiotensin II-1 receptors mediate both vasoconstrictor and hypertrophic responses in rat aortic smooth muscle cells. Receptor 1991, 1:133-140.
5. Stouffer G.A., Owens G.K. Angiotensin II-induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-beta. Circ. Res. 1992, 70:820-828.
6. Hughes J., Roth R.H. Evidence that angiotensin enhances transmitter release during sympathetic nerve stimulation. Br. J. Pharmacol. 1971, 41:239-255.
7. Reams G.P., Bauer J.H. Angiotensin II potentiates the vasoconstrictive effect of norepinephrine in normotensive and hypertensive man. J. Clin. Hypertens. 1987, 3:610-616.
8. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52:415-472.
9. Paradis P., Dali-Youcef N., Paradis F.W., Thibault G., Nemer M. Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:931-936.
10. Zhong J., Basu R., Guo D., Chow F.L., Byrns S., Schuster M., et al. Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction. Circulation 2010, 122:717-728.
11. Wang W., Bodiga S., Das S.K., Lo J., Patel V., Oudit G.Y. Role of ACE2 in diastolic and systolic heart failure. Heart Fail. Rev. 2012, 17:683-691.
12. Iyer S.N., Ferrario C.M., Chappell M.C. Angiotensin-(1-7) contributes to the antihypertensive effects of blockade of the renin-angiotensin system. Hypertension 1998, 31:356-361.
13. Stanley W.C., Recchia F.A., Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol. Rev. 2005, 85:1093-1129.
14. Lopaschuk G.D., Ussher J.R., Folmes C.D., Jaswal J.S., Stanley W.C. Myocardial fatty acid metabolism in health and disease. Physiol. Rev. 2010, 90:207-258.
15. Allard M.F., Schonekess B.O., Henning S.L., English D.R., Lopaschuk G.D. Contribution of oxidative metabolism and glycolysis to ATP production in hypertrophied hearts. Am. J. Physiol. 1994, 267:H742-H750.
16. Mori J., Basu R., McLean B.A., Das S.K., Zhang L., Patel V.B., et al. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ. Heart Fail. 2012, 5:493-503.
17. Lewis G.D., Asnani A., Gerszten R.E. Application of metabolomics to cardiovascular biomarker and pathway discovery. J. Am. Coll. Cardiol. 2008, 52:117-123.
18. Turer A.T. Using metabolomics to assess myocardial metabolism and energetics in heart failure. J. Mol. Cell. Cardiol. 2013, 55:12-18.
19. Biala A., Tauriainen E., Siltanen A., Shi J., Merasto S., Louhelainen M., et al. Resveratrol induces mitochondrial biogenesis and ameliorates Ang II-induced cardiac remodeling in transgenic rats harboring human renin and angiotensinogen genes. Blood Press. 2010, 19:196-205.
20. Larkin J.E., Frank B.C., Gaspard R.M., Duka I., Gavras H., Quackenbush J. Cardiac transcriptional response to acute and chronic angiotensin II treatments. Physiol. Genomics 2004, 18:152-166.
21. de Cavanagh E.M., Ferder M., Inserra F., Ferder L. Angiotensin II, mitochondria, cytoskeletal, and extracellular matrix connections: an integrating viewpoint. Am. J. Physiol. Heart Circ. Physiol. 2009, 296:H550-H558.
22. Chatham J.C., Forder J.R. A 13C-NMR study of glucose oxidation in the intact functioning rat heart following diabetes-induced cardiomyopathy. J. Mol. Cell. Cardiol. 1993, 25:1203-1213.
23. Randle P.J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35years. Diabetes Metab. Rev. 1998, 14:263-283.
24. Pellieux C., Aasum E., Larsen T.S., Montessuit C., Papageorgiou I., Pedrazzini T., et al. Overexpression of angiotensinogen in the myocardium induces downregulation of the fatty acid oxidation pathway. J. Mol. Cell. Cardiol. 2006, 41:459-466.
25. Sekiguchi K., Tian Q., Ishiyama M., Burchfield J., Gao F., Mann D.L., et al. Inhibition of PPAR-alpha activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF-beta/Smad3. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H1443-H1451.
26. Pellieux C., Montessuit C., Papageorgiou I., Lerch R. Angiotensin II downregulates the fatty acid oxidation pathway in adult rat cardiomyocytes via release of tumour necrosis factor-alpha. Cardiovasc. Res. 2009, 82:341-350.
27. Mori J., Alrob O.A., Wagg C.S., Harris R.A., Lopaschuk G.D., Oudit G.Y. Ang II causes insulin resistance and induces cardiac metabolic switch and inefficiency: a critical role of PDK4. Am J Physiol Heart Circ Physiol 2013, 304:H1103-H1113.
28. Tham D.M., Martin-McNulty B., Wang Y.X., Wilson D.W., Vergona R., Sullivan M.E., et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol. Genomics 2002, 11:21-30.
29. de Cavanagh E.M., Inserra F., Ferder L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria?. Cardiovasc. Res. 2011, 89:31-40.
30. Atherton H.J., Dodd M.S., Heather L.C., Schroeder M.A., Griffin J.L., Radda G.K., et al. Role of pyruvate dehydrogenase inhibition in the development of hypertrophy in the hyperthyroid rat heart: a combined magnetic resonance imaging and hyperpolarized magnetic resonance spectroscopy study. Circulation 2011, 123:2552-2561.
31. Stuck B.J., Lenski M., Bohm M., Laufs U. Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase. J. Biol. Chem. 2008, 283:32562-32569.
32. Neubauer S. The failing heart-an engine out of fuel. N. Engl. J. Med. 2007, 356:1140-1151.
33. Ingwall J.S. Energy metabolism in heart failure and remodelling. Cardiovasc. Res. 2009, 81:412-419.
34. Schroeder M.A., Lau A.Z., Chen A.P., Gu Y., Nagendran J., Barry J., et al. Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart. Eur. J. Heart Fail. 2013, 15:130-140.
35. Taylor M., Wallhaus T.R., Degrado T.R., Russell D.C., Stanko P., Nickles R.J., et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. J. Nucl. Med. 2001, 42:55-62.
36. Stanley W.C., Chandler M.P. Energy metabolism in the normal and failing heart: potential for therapeutic interventions. Heart Fail. Rev. 2002, 7:115-130.
37. Recchia F.A., McConnell P.I., Bernstein R.D., Vogel T.R., Xu X., Hintze T.H. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ. Res. 1998, 83:969-979.
38. de Brouwer K.F., Degens H., Aartsen W.M., Lindhout M., Bitsch N.J., Gilde A.J., et al. Specific and sustained down-regulation of genes involved in fatty acid metabolism is not a hallmark of progression to cardiac failure in mice. J. Mol. Cell. Cardiol. 2006, 40:838-845.
39. Kato T., Niizuma S., Inuzuka Y., Kawashima T., Okuda J., Tamaki Y., et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ. Heart Fail. 2010, 3:420-430.
40. Mamas M.A., Deaton C., Rutter M.K., Yuille M., Williams S.G., Ray S.G., et al. Impaired glucose tolerance and insulin resistance in heart failure: underrecognized and undertreated?. J. Card. Fail. 2010, 16:761-768.
41. Doehner W., Rauchhaus M., Ponikowski P., Godsland I.F., von Haehling S., Okonko D.O., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J. Am. Coll. Cardiol. 2005, 46:1019-1026.
42. Wong A.K., AlZadjali M.A., Choy A.M., Lang C.C. Insulin resistance: a potential new target for therapy in patients with heart failure. Cardiovasc. Ther. 2008, 26:203-213.
43. Caldiz C.I., de Cingolani G.E. Insulin resistance in adipocytes from spontaneously hypertensive rats: effect of long-term treatment with enalapril and losartan. Metabolism 1999, 48:1041-1046.
44. Ogihara T., Asano T., Ando K., Chiba Y., Sakoda H., Anai M., et al. Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling. Hypertension 2002, 40:872-879.
45. Motley E.D., Eguchi K., Gardner C., Hicks A.L., Reynolds C.M., Frank G.D., et al. Insulin-induced Akt activation is inhibited by angiotensin II in the vasculature through protein kinase C-alpha. Hypertension 2003, 41:775-780.
46. Velloso L.A., Folli F., Sun X.J., White M.F., Saad M.J., Kahn C.R. Cross-talk between the insulin and angiotensin signaling systems. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:12490-12495.
47. Fujio Y., Nguyen T., Wencker D., Kitsis R.N., Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000, 101:660-667.
48. Stabile E., Zhou Y.F., Saji M., Castagna M., Shou M., Kinnaird T.D., et al. Akt controls vascular smooth muscle cell proliferation in vitro and in vivo by delaying G1/S exit. Circ. Res. 2003, 93:1059-1065.
49. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
50. Folli F., Kahn C.R., Hansen H., Bouchie J.L., Feener E.P. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J. Clin. Invest. 1997, 100:2158-2169.
51. Latronico M.V., Costinean S., Lavitrano M.L., Peschle C., Condorelli G. Regulation of cell size and contractile function by AKT in cardiomyocytes. Ann. N. Y. Acad. Sci. 2004, 1015:250-260.
52. Walsh K. Akt signaling and growth of the heart. Circulation 2006, 113:2032-2034.
53. Allard M.F., Wambolt R.B., Longnus S.L., Grist M., Lydell C.P., Parsons H.L., et al. Hypertrophied rat hearts are less responsive to the metabolic and functional effects of insulin. Am. J. Physiol. Endocrinol. Metab. 2000, 279:E487-E493.
54. Paternostro G., Pagano D., Gnecchi-Ruscone T., Bonser R.S., Camici P.G. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc. Res. 1999, 42:246-253.
55. Zhu Y., Pereira R.O., O'Neill B.T., Riehle C., Ilkun O., Wende A.R., et al. Cardiac PI3K-Akt impairs insulin-stimulated glucose uptake independent of mTORC1 and GLUT4 translocation. Mol Endocrinol 2013, 27:172-184.
56. Abel E.D. Glucose transport in the heart. Front. Biosci. 2004, 9:201-215.
57. Montessuit C., Thorburn A. Transcriptional activation of the glucose transporter GLUT1 in ventricular cardiac myocytes by hypertrophic agonists. J. Biol. Chem. 1999, 274:9006-9012.
58. Abel E.D., Kaulbach H.C., Tian R., Hopkins J.C., Duffy J., Doetschman T., et al. Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. J. Clin. Invest. 1999, 104:1703-1714.
59. Zhou M., Sevilla L., Vallega G., Chen P., Palacin M., Zorzano A., et al. Insulin-dependent protein trafficking in skeletal muscle cells. Am. J. Physiol. 1998, 275:E187-E196.
60. Barthel A., Nakatani K., Dandekar A.A., Roth R.A. Protein kinase C modulates the insulin-stimulated increase in Akt1 and Akt3 activity in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 1998, 243:509-513.
61. Worrall D.S., Olefsky J.M. The effects of intracellular calcium depletion on insulin signaling in 3T3-L1 adipocytes. Mol. Endocrinol. 2002, 16:378-389.
62. Ikushima M., Ishii M., Ohishi M., Yamamoto K., Ogihara T., Rakugi H., et al. ANG II inhibits insulin-mediated production of PI 3,4,5-trisphosphates via a Ca2+-dependent but PKC-independent pathway in the cardiomyocytes. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H680-H689.
63. von Lewinski D., Bruns S., Walther S., Kogler H., Pieske B. Insulin causes [Ca2+]i-dependent and [Ca2+]i-independent positive inotropic effects in failing human myocardium. Circulation 2005, 111:2588-2595.
64. Robertson A.L., Khairallah P.A. Angiotensin II: rapid localization in nuclei of smooth and cardiac muscle. Science 1971, 172:1138-1139.
65. Gwathmey T.M., Shaltout H.A., Pendergrass K.D., Pirro N.T., Figueroa J.P., Rose J.C., et al. Nuclear angiotensin II type 2 (AT2) receptors are functionally linked to nitric oxide production. Am. J. Physiol. Renal Physiol. 2009, 296:F1484-F1493.
66. Abadir P.M., Foster D.B., Crow M., Cooke C.A., Rucker J.J., Jain A., et al. Identification and characterization of a functional mitochondrial angiotensin system. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:14849-14854.
67. Mazzocchi G., Robba C., Rebuffat P., Nussdorfer G.G. Investigations on the turnover of adrenocortical mitochondria. XV. A stereological study of the effect of chronic treatment with angiotensin II on the size and number of the mitochondria in the zona glomerulosa of the rat. Cell Tissue Res. 1980, 210:333-337.
68. Tabony A.M., Yoshida T., Galvez S., Higashi Y., Sukhanov S., Chandrasekar B., et al. Angiotensin II upregulates protein phosphatase 2Calpha and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting. Hypertension 2011, 58:643-649.
69. Wiemer G., Scholkens B.A., Wagner A., Heitsch H., Linz W. The possible role of angiotensin II subtype AT2 receptors in endothelial cells and isolated ischemic rat hearts. J. Hypertens. Suppl. 1993, 11:S234-S235.
70. Ratliff B.B., Sekulic M., Rodebaugh J., Solhaug M.J. Angiotensin II regulates NOS expression in afferent arterioles of the developing porcine kidney. Pediatr. Res. 2010, 68:29-34.
71. Abadir P.M., Carey R.M., Siragy H.M. Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 2003, 42:600-604.
72. Bates T.E., Loesch A., Burnstock G., Clark J.B. Immunocytochemical evidence for a mitochondrially located nitric oxide synthase in brain and liver. Biochem. Biophys. Res. Commun. 1995, 213:896-900.
73. Valdez L.B., Boveris A. Mitochondrial nitric oxide synthase, a voltage-dependent enzyme, is responsible for nitric oxide diffusion to cytosol. Front. Biosci. 2007, 12:1210-1219.
74. Dai D.F., Rabinovitch P.S., Ungvari Z. Mitochondria and cardiovascular aging. Circ. Res. 2012, 110:1109-1124.
75. Dai D.F., Johnson S.C., Villarin J.J., Chin M.T., Nieves-Cintron M., Chen T., et al. Mitochondrial oxidative stress mediates angiotensin II-induced cardiac hypertrophy and Galphaq overexpression-induced heart failure. Circ. Res. 2011, 108:837-846.
76. Ago T., Kuroda J., Pain J., Fu C., Li H., Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ. Res. 2010, 106:1253-1264.
77. Balteau M., Tajeddine N., de Meester C., Ginion A., Des Rosiers C., Brady N.R., et al. NADPH oxidase activation by hyperglycaemia in cardiomyocytes is independent of glucose metabolism but requires SGLT1. Cardiovasc. Res. 2011, 92:237-246.
78. Garcia-Ruiz C., Colell A., Mari M., Morales A., Fernandez-Checa J.C. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J. Biol. Chem. 1997, 272:11369-11377.
79. Gudz T.I., Tserng K.Y., Hoppel C.L. Direct inhibition of mitochondrial respiratory chain complex III by cell-permeable ceramide. J. Biol. Chem. 1997, 272:24154-24158.
80. Rosca M.G., Tandler B., Hoppel C.L. Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol 2013, 55:31-41.
81. Kuma A., Hatano M., Matsui M., Yamamoto A., Nakaya H., Yoshimori T., et al. The role of autophagy during the early neonatal starvation period. Nature 2004, 432:1032-1036.
82. Nakai A., Yamaguchi O., Takeda T., Higuchi Y., Hikoso S., Taniike M., et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nat. Med. 2007, 13:619-624.
83. Zhao T., Huang X., Han L., Wang X., Cheng H., Zhao Y., et al. Central role of mitofusin 2 in autophagosome-lysosome fusion in cardiomyocytes. J. Biol. Chem. 2012, 287:23615-23625.
84. Bach D., Pich S., Soriano F.X., Vega N., Baumgartner B., Oriola J., et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J. Biol. Chem. 2003, 278:17190-17197.
85. Pan W., Zhong Y., Cheng C., Liu B., Wang L., Li A., et al. MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS One 2013, 8:e53950.
86. Zhu H., Tannous P., Johnstone J.L., Kong Y., Shelton J.M., Richardson J.A., et al. Cardiac autophagy is a maladaptive response to hemodynamic stress. J. Clin. Invest. 2007, 117:1782-1793.
87. Schwer B., Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell Metab. 2008, 7:104-112.
88. Borradaile N.M., Pickering J.G. NAD(+), sirtuins, and cardiovascular disease. Curr. Pharm. Des. 2009, 15:110-117.
89. Dali-Youcef N., Lagouge M., Froelich S., Koehl C., Schoonjans K., Auwerx J. Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann. Med. 2007, 39:335-345.
90. Miyazaki R., Ichiki T., Hashimoto T., Inanaga K., Imayama I., Sadoshima J., et al. SIRT1, a longevity gene, downregulates angiotensin II type 1 receptor expression in vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1263-1269.
91. Ota H., Eto M., Kano M.R., Ogawa S., Iijima K., Akishita M., et al. Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2008, 28:1634-1639.
92. Kackstein K., Teren A., Matsumoto Y., Mangner N., Mobius-Winkler S., Linke A., et al. Impact of angiotensin II on skeletal muscle metabolism and function in mice: Contribution of IGF-1, Sirtuin-1 and PGC-1alpha. Acta Histochem 2013, 115:363-370.
93. Jiang H., Khan S., Wang Y., Charron G., He B., Sebastian C., et al. SIRT6 regulates TNF-alpha secretion through hydrolysis of long-chain fatty acyl lysine. Nature 2013, 496:110-113.
94. Cai Y., Yu S.S., Chen S.R., Pi R.B., Gao S., Li H., et al. Nmnat2 protects cardiomyocytes from hypertrophy via activation of SIRT6. FEBS Lett. 2012, 586:866-874.
95. Liu T.F., Vachharajani V.T., Yoza B.K., McCall C.E. NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response. J. Biol. Chem. 2012, 287:25758-25769.
96. Michan S., Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem. J. 2007, 404:1-13.
97. Koyama T., Kume S., Koya D., Araki S., Isshiki K., Chin-Kanasaki M., et al. SIRT3 attenuates palmitate-induced ROS production and inflammation in proximal tubular cells. Free Radic. Biol. Med. 2011, 51:1258-1267.
98. Someya S., Yu W., Hallows W.C., Xu J., Vann J.M., Leeuwenburgh C., et al. Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. Cell 2010, 143:802-812.
99. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., Vassilopoulos A., et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14447-14452.
100. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009, 119:524-530.
101. Santos R.A., Ferreira A.J., Verano-Braga T., Bader M. Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system. J. Endocrinol. 2013, 216:R1-R17.
102. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 2000, 87:E1-E9.
103. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-828.
104. Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M.J., et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp. Physiol. 2005, 90:783-790.
105. Diez-Freire C., Vazquez J. Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol. Genomics 2006, 27:12-19.
106. Sampaio W.O., Nascimento A.A., Santos R.A. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am. J. Physiol. Heart Circ. Physiol. 2003, 284:H1985-H1994.
107. Botelho-Santos G.A., Sampaio W.O., Reudelhuber T.L., Bader M., Campagnole-Santos M.J. Souza dos Santos RA. Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2485-H2490.
108. Mahon J.M., Carr R.D., Nicol A.K., Henderson I.W. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. J. Hypertens. 1994, 12:1377-1381.
109. Porsti I., Bara A.T., Busse R., Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br. J. Pharmacol. 1994, 111:652-654.
110. Brosnihan K.B., Li P., Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996, 27:523-528.
111. Paula R.D., Lima C.V., Khosla M.C., Santos R.A. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension 1995, 26:1154-1159.
112. Ueda S., Masumori-Maemoto S., Wada A., Ishii M., Brosnihan K.B., Umemura S. Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. J. Hypertens. 2001, 19:2001-2009.
113. Santiago N.M., Guimaraes P.S., Sirvente R.A., Oliveira L.A., Irigoyen M.C., Santos R.A., et al. Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 2010, 55:889-896.
114. Ferreira A.J., Santos R.A., Almeida A.P. Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001, 38:665-668.
115. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 105:1548-1550.
116. Mercure C., Yogi A., Callera G.E., Aranha A.B., Bader M., Ferreira A.J., et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circ. Res. 2008, 103:1319-1326.
117. Tallant E.A., Ferrario C.M., Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H1560-H1566.
118. Iwata M., Cowling R.T., Gurantz D., Moore C., Zhang S., Yuan J.X., et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am. J. Physiol. Heart Circ. Physiol. 2005, 289:H2356-H2363.
119. Castro C.H., Santos R.A., Ferreira A.J., Bader M., Alenina N., Almeida A.P. Effects of genetic deletion of angiotensin-(1-7) receptor Mas on cardiac function during ischemia/reperfusion in the isolated perfused mouse heart. Life Sci. 2006, 80:264-268.
120. Santos R.A., Castro C.H., Gava E., Pinheiro S.V., Almeida A.P., Paula R.D., et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006, 47:996-1002.
121. Oudit G.Y., Kassiri Z., Patel M.P., Chappell M., Butany J., Backx P.H., et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 2007, 75:29-39.
122. Oudit G.Y., Liu G.C., Zhong J., Basu R., Chow F.L., Zhou J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes 2010, 59:529-538.
123. Ko S.H., Kwon H.S., Kim S.R., Moon S.D., Ahn Y.B., Song K.H., et al. Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem. Biophys. Res. Commun. 2004, 316:114-122.
124. Lau T., Carlsson P.O., Leung P.S. Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004, 47:240-248.
125. Carlsson P.O., Berne C., Jansson L. Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 1998, 41:127-133.
126. Bindom S.M., Hans C.P., Xia H., Boulares A.H., Lazartigues E. Angiotensin I-converting enzyme type 2 (ACE2) gene therapy improves glycemic control in diabetic mice. Diabetes 2010, 59:2540-2548.
127. Takeda M., Yamamoto K., Takemura Y., Takeshita H., Hongyo K., Kawai T., et al. Loss of ACE2 Exaggerates High-Calorie Diet-Induced Insulin Resistance by Reduction of GLUT4 in Mice. Diabetes 2013, 62:223-233.
128. Patel V.B., Bodiga S., Basu R., Das S.K., Wang W., Wang Z., et al. Loss of angiotensin-converting enzyme-2 exacerbates diabetic cardiovascular complications and leads to systolic and vascular dysfunction: a critical role of the angiotensin II/AT1 receptor axis. Circ. Res. 2012, 110:1322-1335.
129. Giani J.F., Gironacci M.M., Munoz M.C., Pena C., Turyn D., Dominici F.P. Angiotensin-(1 7) stimulates the phosphorylation of JAK2, IRS-1 and Akt in rat heart in vivo: role of the AT1 and Mas receptors. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1154-H1163.
130. Paulus W.J., van Ballegoij J.J. Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J. Am. Coll. Cardiol. 2010, 55:526-537.
131. Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., et al. Irbesartan in patients with heart failure and preserved ejection fraction. N. Engl. J. Med. 2008, 359:2456-2467.
132. Solomon S.D., Zile M., Pieske B., Voors A., Shah A., Kraigher-Krainer E., et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet 2012, 380:1387-1395.
133. Urata H., Healy B., Stewart R.W., Bumpus F.M., Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ. Res. 1990, 66:883-890.
134. Urata H., Kinoshita A., Misono K.S., Bumpus F.M., Husain A. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J. Biol. Chem. 1990, 265:22348-22357.
135. Wei C.C., Hase N., Inoue Y., Bradley E.W., Yahiro E., Li M., et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J. Clin. Invest. 2010, 120:1229-1239.
136. Rett K., Wicklmayr M., Dietze G.J. Metabolic effects of kinins: historical and recent developments. J. Cardiovasc. Pharmacol. 1990, 15(Suppl. 6):S57-S59.